Monoclonal antibodies targeting IL-5/5R and IL-4/13 pathways showed steroid-sparing effects and favorable safety for controlling eosinophilic myocarditis.
Do monoclonal antibodies targeting IL-5/5R or IL-4/13 pathways provide steroid-sparing effects and safe disease control in patients with eosinophilic myocarditis?
Monoclonal antibodies targeting IL-5/5R or IL-4/13 pathways may offer a safe, steroid-sparing treatment option for eosinophilic myocarditis.
Absolute Event Rate: 0% vs 0%
In EM within eosinophilic disease, anti-IL-5/5R and anti-IL-4/13 mAbs showed steroid-sparing effects and favorable safety, suggesting potential benefit for disease control.
Giordani et al. (Mon,) reported a other. Monoclonal antibodies targeting IL-5/5R and IL-4/13 pathways showed steroid-sparing effects and favorable safety for controlling eosinophilic myocarditis.